Switching off protein may boost efficacy of cancer treatment: Study

Image
Press Trust of India Washington
Last Updated : Aug 01 2018 | 3:50 PM IST

Inhibiting a previously known protein could reduce tumour burden and enhance the effectiveness of immunotherapy treatments, a study has found.

Immunotherapy is a type of cancer treatment that boosts the body's natural defences to fight cancer.

Scientists at Johns Hopkins Kimmel Cancer Center in the US used mice genetically engineered to lack Yes-associated protein, or YAP, in several T-cell populations, including regulatory T-cells, known as Tregs.

This was the first time the relationship between YAP and Tregs has been explored, according to the research published in the journal Cancer Discovery.

Tregs are important for health, because they prevent autoimmune diseases but can be a major obstacle in the mounting of immune responses to tumours and immunotherapy.

YAP can be found in a subset of those regulatory T-cells.

Scientists tested the antitumour effects of YAP inhibitors alone and in combination with immunotherapies.

The results showed YAP plays a role in the suppression of antitumour immunity by Tregs and demonstrated by turning off YAP's abilities, tumour killing with less restrained immune cells is possible.

Fan Pan, an associate professor at Johns Hopkins Medicine, said that blocking YAP or the signalling pathways under its control boosted the effects of both a tumour vaccine and a checkpoint inhibitor (anti-PD1 antibody) to produce even stronger antitumour activity.

He said the approach of therapeutically targeting YAP was effective over a broad scope of cancer types in mice.

Tregs are notorious for dampening the effectiveness of tumour-directed immunity in cancer patients, researchers said.

The finding may pave the way for a new and promising strategy to unleash the patient immune response from the stifling grip of suppressor cell control, they said.

The researchers are optimistic that further work could lead to effective YAP-targeting immunotherapies for cancer.

They said that therapies aimed at enhancing YAP activity may have potential use for the treatment of autoimmune diseases.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 01 2018 | 3:50 PM IST

Next Story